In vitro activity of novel rifamycins against gram-positive clinical isolates.

Abstract

We describe novel rifamycins that have improved activity, compared with rifampin, against clinical isolates of staphylococci and streptococci, with MIC(90)s of 0.008 and 0.0005 microg/ml, respectively. This enhanced antibacterial activity, along with their potential lack of drug-drug interactions, are considerations that suggest the potential of these novel rifamycins in combination therapy to treat serious Gram-positive infections.

• Authors: Christopher K Murphy, Elena Karginova, Dan Sahm, David M Rothstein
• Journal: The Journal of antibiotics (J Antibiot (Tokyo)) Vol. 60 Issue 9 Pg. 572-6 (Sep 2007) ISSN: 0021-8820 [Print] England
• PMID: 17917240 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Rifamycins
• Cytochrome P-450 Enzyme System

Topics

• Anti-Bacterial Agents (pharmacology)
• Cytochrome P-450 Enzyme System (drug effects)
• Drug Interactions
• Enterococcus faecalis (drug effects)
• Enterococcus faecium (drug effects)
• Gram-Positive Cocci (drug effects)
• Microbial Sensitivity Tests
• Rifamycins (pharmacology)
• Staphylococcus aureus (drug effects)
• Staphylococcus epidermidis (drug effects)
• Streptococcus agalactiae (drug effects)
• Streptococcus pneumoniae (drug effects)
• Streptococcus pyogenes (drug effects)